Use and abuse of statistics in tobacco industry-funded research on standardised packaging

Anthony A Laverty,1 Pascal Diethelm,2 Nicholas S Hopkinson,3 Hilary C Watt,1 Martin McKee4

ABSTRACT

In this commentary we consider the validity of tobacco industry-funded research on the effects of standardised packaging in Australia. As the first country to introduce standardised packs, Australia is closely watched, and Philip Morris International has recently funded two studies into the impact of the measure on smoking prevalence. Both of these papers are flawed in conception as well as design but have nonetheless been widely publicised as cautionary tales against standardised pack legislation. Specifically, we focus on the low statistical significance of the analytical methods used and the assumption that standardised packaging should have an immediate large impact on smoking prevalence.

An increasing number of countries are considering legislation to enforce standardised tobacco packaging (also known as ‘plain packaging’) consistent with the Framework Convention on Tobacco Control provision to prevent false, misleading or deceptive labelling.1 Tobacco industry resistance to such legislation is increasing, as demonstrated by their funding of two working papers which claim that standardised packaging has had no impact on smoking prevalence in Australia, the first country to have successfully introduced this measure.2,3 The first working paper focused on children aged 14–17 years and the second on adults. The former has been criticised thoroughly elsewhere4–6 but although the authors reject these criticisms,7 the second shares many of the same flaws and biases. There are two core issues to consider. The first is that the introduction of standardised packaging is not expected to have a sudden impact on smoking prevalence, but rather to impact on the rate of smoking uptake. The second is that both papers are not in fact powered to detect any plausible impact. We examine the arguments in detail and focus on the second paper, on adults, though our observations apply to both.

Both working papers use the Roy Morgan Single Source (Australia) data set, from January 2001 to December 2013, and calculate monthly smoking prevalence over the period. The authors assert that the data for the working paper on children are publicly available, although they have to be purchased. They note that data for the adult working paper were “provided to us by Philip Morris International.”

In both papers, the authors first construct a linear time trend of the decline in smoking prevalence over an extended period before the introduction of standardised packaging, which has been driven by a range of tobacco control measures. The papers then assess whether the observed decline after the standardised packaging measure was introduced significantly exceeds the level predicted by the linear trend. To do so they assess whether the deviations from this trend are different in the year after the legislation compared to the year before, and finally they compute 90% CIs around the monthly prevalence figures to see if these span the extended trend line. These working papers show that the declining trend in smoking prevalence averaged 0.48 percentage points per year at all ages in Australia over the period (and 0.44% for children) and continues to fall at a similar rate after the introduction of standardised packaging. This is interpreted as a lack of evidence for effectiveness of the measure.

Such a continued decline is likely a positive sign given that, as prevalence reaches very low levels, the proportion of more addicted smokers who find it more difficult to quit increases.8 This therefore means that a continuation of the same rate of decline in this context, rather than a levelling off, in fact likely represents an increase in effectiveness of tobacco control measures. Any determination of statistical power in the analysis presented needs to rest on the assumption that the new legislation would increase the rate of decline, rather than simply retaining it.

A sudden decline in smoking prevalence was not envisaged in this legislation,9 with any effect expected to be predominantly around initiation of smoking rather than rates of quitting. Experts who had commented on the legislation prior to implementation (in a research paper cited by the authors in their working paper on adults) estimated that even 2 years would be too short a timespan in which to witness the full impact of standardised packaging measures.10 Hence, the immediate effect being sought is implausible, partly due to these time lags and partly due to the inadequacy of prevalence as a measure in this context. The nature of addiction is such that any impact on quitting is likely to take place over several years and a small increase in the rate of decline may be more realistic than an immediate dramatic fall in prevalence.

Even if the assumption of an immediate decline is accepted, the analysis of statistical power in both papers is opaque. The authors claim that ‘the power of our inference models is remarkably high’, supporting their argument with results of Monte Carlo simulations, and calculating a power of 0.85 to detect a 0.5% reduction in prevalence. These calculations are based on achieving statistical significance in any 1 of 12 tests, and the authors fail to emphasise that these high-power calculations result from considering all tests simultaneously.
Figure 1 Illustration of sudden and gradual decline models used in power
calculation (Δ=prevalence reduction
being tested; K&W, Kaul and Wolf).

Table 1 Comparison of the power claimed by Kaul and Wolf in
their second paper on adults with the actual power (t test with
p=0.05, as this is the best they can achieve, invoking a gradual
effect of standardised packaging, and obtained using Monte Carlo
simulation with 50 000 iterations)

<table>
<thead>
<tr>
<th>Effect size (percentage point reduction)</th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Claimed</td>
</tr>
<tr>
<td>0.25</td>
<td>0.67</td>
</tr>
<tr>
<td>0.50</td>
<td>0.85</td>
</tr>
<tr>
<td>0.75</td>
<td>0.96</td>
</tr>
<tr>
<td>1.00</td>
<td>0.99</td>
</tr>
</tbody>
</table>

They fail to quote the corresponding significance level, which
needs to be on the same basis (combined across all 12 tests), and
erroneously claim their power applies at the 5% significance
level. While the significance level associated with one CI being
to 12—nevertheless, the signifi-
cance level would still be approximately 50% for 13 tests.

For the second paper on adults, the authors also amended the
overall definition of significance used to calculate power (ie, they
remove December 2012 from their analysis), which avoids overall
significance favouring standardised packaging (by the definition
that they use to calculate power, based on significance on any one
of several tests). Such amendments raise additional concerns about
the ad hoc nature of the approach used in these working papers.

A more suitable model would therefore be one in which the
potential impact of standardised packaging effect is gradual,
increasing linearly to reach the predicted decrease at the end of
a given period (figure 1). We have performed a Monte Carlo
simulation using the gradual effect model just described and a
t test, which is everywhere more powerful than the CI method.
The power figures we have obtained are shown in table 1, side
by side with the power figures published in the second working
paper. One can see that they are quite different. This table
emphasises the issues with their claim that “From January 2013
on, even very powerful statistical techniques no longer can pick
up any change from the pre-existing trend.” Simply put, the
data—although suggestive of a standardised packaging effect—and the method used to analyse it, do not permit any inference
one way or the other. The same can be said of their first
working paper on children. Although data on uptake of
smoking specifically rather than prevalence would allow a stron-
ger research design, a statistical analysis of this gradual effect
would be a more appropriate use of the available data.

Both of these working papers have been heavily publicised by
the tobacco industry, continuing a tradition of misrepresenting
evidence.1 The publication of the adult paper on the website of
the University of Zürich was accompanied by a media release
issued by the Institute for Policy Evaluation, which had been
commissioned by Philip Morris International to carry out the
study. This claimed that “The experts found no evidence for a
standardized packaging effect on smoking prevalence using
standard techniques for statistical analysis, in particular requir-
ing a statistical significance level of 5%, which is the standard in
applied research.” Several major tobacco companies have addi-
tionally referred to these papers in their response to the UK
consultation on standardised packaging, for example, Philip
Morris Limited submitted that:

In both studies, using standard techniques for statistical analysis
and applying the standard statistical significance level of 5%, the
experts found no evidence that “standardised packaging” had had
an effect on smoking prevalence among Australians aged 14 to 17
years old (in the case of the March study) or Australians aged 14
and above (in the case of the June study). Kaul and Wolf con-
formed that if there had been an effect in reality [...] it would have
been reflected in the data. According to the study, however, no
effect was found.12

The publication of the initial paper on children was in the
lead up to the publication of the Chantler review on standar-
dised packaging in England, which, despite this, supported it as
a means to reduce smoking. There is a continuing need to guard
against such misrepresentations of the evidence as other coun-
tries look to Australia to inform their own policies of standar-
dised packaging. Nevertheless, despite such opposition from the
tobacco industry the most recent Australian government data
show that smoking rates have in fact fallen to a historic low of
12.8%.13 There is also additional positive news in that other
countries, including the UK, New Zealand and Ireland, are also
now moving towards the introduction of standardised packaging
to protect the health of their populations.
Contributors PD analysed the data. AAL and PD produced the first draft of the manuscript with input from HCW, NSH and MM. All authors made significant contributions to the writing of the manuscript and critical interpretation of the data.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data from the original papers comes from the Roy Morgan Single Source (Australia) dataset, which is available for a fee. The data used in this manuscript has been ‘reverse engineered’ from published material—details will be posted on the website of PD.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
5 Dierhelm P, McKee M. Tobacco industry-funded research on standardised packaging: there are none so blind as those who will not see! Tob Control 2014. Published Online First: 7 Jul 2014. doi:10.1136/tobaccocontrol-2014-051734
Use and abuse of statistics in tobacco industry-funded research on standardised packaging
Anthony A Laverty, Pascal Diethelm, Nicholas S Hopkinson, Hilary C Watt and Martin McKee

Tob Control published online February 3, 2015

Updated information and services can be found at:
http://tobaccocontrol.bmj.com/content/early/2015/03/05/tobaccocontrol-2014-052051

These include:

References
This article cites 5 articles, 1 of which you can access for free at:
http://tobaccocontrol.bmj.com/content/early/2015/03/05/tobaccocontrol-2014-052051#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercially. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/